Deverra Therapeutics
Blood & Organ Banks · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1600 Fairview Ave E Ste 300, Seattle, Wa...Phone Number
(206) 519-5300Website
www.deverratx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
2
1
1
About Deverra Therapeutics
Deverra Therapeutics is a clinical-stage biotechnology company focused on developing universal donor cell therapy treatments to combat cancer and other life-threatening diseases. Their innovative platform technology utilizes healthy donor umbilical cord blood cells to create allogeneic cellular immunotherapies that do not require donor-patient matching. With over 20 years of experience, Deverra offers a diverse pipeline of therapies, including hematopoietic stem & progenitor cell immunotherapy and natural killer cell products, aimed at improving patient outcomes. The company is committed to making these therapies accessible and cost-effective for all patients.Explore more
Deverra Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Deverra Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Deverra Therapeutics is spiking on competitors!
Click to see if Deverra Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Deverra Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Deverra Therapeutics
Funding: Get notified immidiatlly once Deverra Therapeutics has new funding data
Earning: See what the market has to say on Deverra Therapeutics recently announced quarterly report
Deverra Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Deverra Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Deverra Therapeutics
Find 3 more new buyers
Compare Similar Companies to Deverra Therapeutics
Compare insights from companies similar to Deverra Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Deverra Therapeutics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Deverra Therapeutics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Deverra Therapeutics.
Deverra Therapeutics Tech Stack
A closer look at the technologies used by Deverra Therapeutics
Deverra Therapeutics News & Media
Seattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapies
Seattle biotech company Deverra Therapeutics is raising cash for its cellular immunotherapies platform that helps doctors treat patients with cancer and other infectious diseases. A new SEC filing reveals that the startup raised about $2.4 million through a mix of debt and warrants. We reached out to the company for more details and will update this story if we hear back. Founded in 2019, Deverra has an exclusive license from Fred Hutchinson Cancer Research CenterCoeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment
Grants totaling approximately $3.5 million will support Deverra's CAR-NK and engineered myeloid cell programs in hematologic malignancies and solid tumors WEXFORD, Pa., Sept. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a...Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug....Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics
Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors Clinical data from AML...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Deverra Therapeutics
Sign Up For FreeTo access detailed company insights
Deverra Therapeutics is a clinical-stage biotechnology company focused on developing universal donor cell therapy treatments to combat cancer and other life-threatening diseases. Their innovative platform technology utilizes healthy donor umbilical cord blood cells to create allogeneic cellular immunotherapies that do not require donor-patient matc... Read More
